-
Mashup Score: 21STRONG HF – A Positive Trial that Does Not Help Clinical Medicine - 4 month(s) ago
The Study of the Week explores the larger question of what are trials for?
Source: www.sensible-med.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 96Beta Blockers Post-MI? No for Me, Even After the ABYSS Trial - 4 month(s) ago
The need for routine beta blockers post MI in contemporary practice has been questioned but a randomized trial of stopping vs continuing suggested they still have a role. John Mandrola, MD, disagrees.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet-
It’s late in London but here’s my hot take of the ABYSS trial #ESCCongress — Okay to stop beta blockers after MI (good EF) https://t.co/hHdjzDHi70
-
-
Mashup Score: 96Beta Blockers Post-MI? No for Me, Even After the ABYSS Trial - 4 month(s) ago
The need for routine beta blockers post MI in contemporary practice has been questioned but a randomized trial of stopping vs continuing suggested they still have a role. John Mandrola, MD, disagrees.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet-
It’s late in London but here’s my hot take of the ABYSS trial #ESCCongress — Okay to stop beta blockers after MI (good EF) https://t.co/hHdjzDHi70
-
-
Mashup Score: 27TEER in Functional MR: Data Deluge, but No Easy Answers - 4 month(s) ago
A third trial of transcatheter edge-to-edge repair in patients with functional mitral regurgitation doesn’t make for easy patient selection writes John Mandrola, MD.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet-
It’s late in London again. Here’s my hot take of the third TEER trial in functional MR, REHAPE HF2 You’d think 3 trials in one space would sort out the answer. #ESCCongress https://t.co/gseSajJCWw
-
-
Mashup Score: 27TEER in Functional MR: Data Deluge, but No Easy Answers - 4 month(s) ago
A third trial of transcatheter edge-to-edge repair in patients with functional mitral regurgitation doesn’t make for easy patient selection writes John Mandrola, MD.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet-
It’s late in London again. Here’s my hot take of the third TEER trial in functional MR, REHAPE HF2 You’d think 3 trials in one space would sort out the answer. #ESCCongress https://t.co/gseSajJCWw
-
-
Mashup Score: 24Mandrola's Five Big Trials to Look for at ESC 2024 - 4 month(s) ago
A sham trial of AF ablation, finerenone in heart failure, and transcatheter edge-to-edge repair of functional mitral regurgitation are among the trials that caught cardiologist John Mandrola’s eye.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet-
Dr Zipes used to say …Mandrola, a broken clock is right twice a day. I was right about this one. 👇🏻 Docs ought to be less enamored w plausibility https://t.co/t4inwRoTzO https://t.co/PIx7dwDci1
-
-
Mashup Score: 94Beta Blockers Post-MI? No for Me, Even After the ABYSS Trial - 4 month(s) ago
The need for routine beta blockers post MI in contemporary practice has been questioned but a randomized trial of stopping vs continuing suggested they still have a role. John Mandrola, MD, disagrees.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet-
It’s late in London but here’s my hot take of the ABYSS trial #ESCCongress — Okay to stop beta blockers after MI (good EF) https://t.co/hHdjzDHi70
-
-
Mashup Score: 1Aug 23 2024 This Week in Cardiology - 4 month(s) ago
Episode · This Week in Cardiology · Suicidal ideation and GLP-1 agonists, a repeat of PARADIGM HF in Chagas CM, CASTLE HTx critical appraisal, and primary prevention of SCD in HF are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Suicidal ideation with GLP-1 Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution https://www.medscape.com/viewarticle/signal-suicidality-glp-1-ra-semaglutide-experts-urge-caution-2024a1000fa7 Disproportionality Analysis from World Health Organization Data on Semaglutide, Liraglutide, and Suicidality Variability in Disproportionality paper https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.668765/full II. PARACHUTE HF: Repeating the Mistakes in PARADIGM HF PARACHUTE HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021 SOLVD https://www.nejm.org/doi/full/10.1056/NEJM1
Source: open.spotify.comCategories: General Medicine News, Hem/OncsTweet-
RT @PerPersvensson: As most weeks, siding with @drjohnm https://t.co/lGqBpYrILk
-
-
Mashup Score: 29Independent NPs and PAs: A Doc's View - 4 month(s) ago
Nurse practitioners and physician assistants increasingly manage patient care independently. While professional physician organizations cry foul, this doctor is not alarmed.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet-
Nearly 800 comments when I argued that you are correct. On average, non-MD care is quite similar https://t.co/qje4h4MIr9 https://t.co/lnLGIr0aRD https://t.co/aBMtCPVmg8
-
-
Mashup Score: 81Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease | NEJM - 4 month(s) ago
Percutaneous coronary revascularization is widely used in improving symptoms and exercise performance in patients with ischemic heart disease and stable angina pectoris. In this study, we compared …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
In my work with @AndrewFoy82 @MRuzieh over at @CVtrials I discovered another shocking trial. Pts with severe CAD. One group gets PTCA (fixed). One group gets tablet (atorvastatin) AVERT trial https://t.co/UVSgbl8PZt Amazingly -- LOOK AT THIS DATA for major adverse events https://t.co/QB83hpMX4a
-
The STRONG-HF trial made me think: "what are trials for?" Study of the Week: https://t.co/8neTt4t7Z9